William Stern, PhD; Nozer Mehta, PhD; and Stephen Carl, PhD; review a highly developed, clinically proven platform technology that enables the oral delivery of peptides, overcoming the hurdles inherent to oral peptide delivery.
DRUG DELIVERY – HEPtune: A Process of Conjugating a Naturally Occurring Sugar Molecule, Heparosan, to a Drug for Enhanced Drug Delivery
Paul L. DeAngelis, PhD, shows how heparosan is a stealthy molecule well suited for use as a drug delivery vehicle due to its natural origin and properties in the body. Therefore, heparosan-modified therapeutics may offer improved pharmacokinetics, drug performance properties, as well as new options for treatment and hope for patients.
DRUG DEVELOPMENT – Analysis & Materials Characterization – Surface Characterization of Pharmaceuticals by X-Ray Photoelectron Spectroscopy
Jeffrey Shallenberger, MS; and Robert W. Lee, PhD; use X-ray photoelectron spectroscopy (a quantitative, surface-sensitive spectroscopy capable of probing the local chemical bonding of inorganic and organic materials) to quantify the amount of an API and two excipients.
EXECUTIVE INTERVIEW – Ariel Pharmaceuticals, Inc: Reducing Shareholder Risk Through Expedited Clinical Development
Executive Summary: Steve Orndorff, President and CEO of Ariel, discusses his company’s drugs in development and plans for the future.
PLATFORM TECHNOLOGY – Tumor-Targeting Platform Delivers the Next Generation of Pediatric Cancer Drugs
Contributor Cindy H. Dubin examines the desperate need for therapies that can address underserved populations, eradicate the cancer state without severe complications, and prolong the lifespan of the patient after diagnosis, and how NanoSmart Pharmaceuticals, with its unique tumor-targeting platform, has taken on that challenge.
Robert Becker, PhD, Chief Research Officer at Aptalis Pharma, discusses Patient Centric Drug Delivery and the company’s role in supporting patient compliance and driving commercial value through new drug formulations.
Dieter Scherer, PhD; Eva Alvarez-Gonzalez, PhD; and Anthony Pettigrew, MSc; examine a proprietary non-protic, aqueous-free ocular delivery system with the potential to provide an alternative approach in particular for poorly soluble drugs.
Jyothi Thundimadathil, PhD, indicates that even though shorter in vivo half-life of peptides is a concern, recent advances in drug delivery systems and peptide modification are expected to override those difficulties.
DRUG DELIVERY – Recent Advancements in Drug Delivery: Novel Formulations & Technologies Offer Improved Treatment Options
Debbie Toscano, Senior Industry Analyst, Frost & Sullivan, highlights a few recent innovative approaches to drug delivery with a focus on some of the therapeutic areas most relevant to the current pharmaceuticals market.
Gerallt Williams, PhD, takes a look at the market forces driving DPI innovation and focuses on a novel solution that has simplicity at the heart of its design, and which hopes to address the growing pressure to reduce healthcare costs, as well as the needs of new markets, arising from emerging economies in South America, India, and China.
EXCLUSIVE ONLINE CONTENT
MilliporeSigma and Roche recently announced they have agreed to renew their current distribution agreement for the Biochemical Reagents and Kapa Biosystems product portfolios, as well as select qPCR & Nucleic Acid Purification products.
Bavarian Nordic A/S recently announced the US Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN smallpox vaccine.
Lonza recently announced another major milestone in its multiproduct partnership with Takeda.
PCI Pharma Services Announces $20-Million Expansion of Biotech Technologies, Including Advanced Injectable Delivery Forms
Leading global biopharmaceutical services provider PCI Pharma Services (PCI) has announced a momentous investment in support of biologic medicines and advanced injectable delivery forms, totaling more than $20 million.
Catalent, Inc. recently announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.